CompletedEarly Phase 1NCT04300127
Pioglitazone for Idiopathic Gastroparesis
Studying Idiopathic gastroparesis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johns Hopkins University
- Principal Investigator
- Glenn J Treisman, MDJohns Hopkins University
- Intervention
- Pioglitazone 30 mg(drug)
- Enrollment
- 14 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2025
Study locations (1)
- Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04300127 on ClinicalTrials.govOther trials for Idiopathic gastroparesis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT04661215Pyloric Sphincter Abnormalities in Patients With Gastroparesis SymptomsJohns Hopkins Bloomberg School of Public Health
- ACTIVE NOT RECRUITINGPHASE2NCT06899217A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.CinDome Pharma, Inc.
- RECRUITINGNCT05981300GpCRC Pediatric Gastroparesis Registry 2Johns Hopkins Bloomberg School of Public Health
- ENROLLING BY INVITATIONNCT06581120GLP_1 RA Ultrasound StudyChildren's Hospital Medical Center, Cincinnati
- RECRUITINGPHASE3NCT06836557Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisVanda Pharmaceuticals
- RECRUITINGPHASE2NCT05621811Different Doses of Naronapride Vs. Placebo in GastroparesisDr. Falk Pharma GmbH
- ENROLLING BY INVITATIONNCT05812339Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and ControlsUniversity of Calgary
- ACTIVE NOT RECRUITINGNCT03626350Prospective Evaluation of the Efficacy and Safety of Submucosal EndoscopyUniversity of Colorado, Denver